close icon

Horizon Pharma Stock Was Cut in Half. Then it Tripled

Horizon Pharma (NASDAQ:HZNP), headquartered in Dublin, Ireland, is a $4.7B biopharmaceutical company operating primarily in the United States. In July 2015, its stock was in the vicinity of $39.50. By May 2017, it was trading under $10 per share.

We first examined Horizon Pharma stock’s prospects in September 2016, when it was searching for direction near the $18 mark. Here is what we found.

Horizon Pharma Elliott Wave analysis

According to our Elliott Wave analysis of HZNP’s weekly logarithmic chart, the rally from under $2 in March 2013 to $39.49 in July 2015 was a textbook five-wave impulse, labeled (1)-(2)-(3)-(4)-(5). This meant the following sharp selloff was probably part of a three-wave (a)-(b)-(c) correction, whose wave (c) down was still remaining.

No matter how good or bad the company’s fundamentals might have been, that wasn’t what we focused on two and a half years ago. The markets are not as rational as some people believe they are. Even the poorest company can go through the roof, and even the strongest can trade in the doldrums sometimes.

Ahead of Horizon Pharma ‘s Elliott Wave Rally

So instead of analyzing the company, we tried to understand the market’s attitude towards it. Back in September 2016, wave (c) was “about to take the stock back to the price area between $9 and $7” and complete the 5-3 wave cycle. The trend was then supposed to resume in the direction of the five-wave impulse. Instead of losing hope, we thought investors should take advantage of this low-risk buying opportunity.

Horizon Pharma climbed to $29.44 last week. The updated chart below visualizes its development since September 2016.

Horizon Pharma Tripled from the Lows in May 2017

Wave (c) dragged the stock down to $9.45. The touted reason for the crash to single digits was the company’s disappointing Q1 2017 report which also included a lowered guidance for the full year. In reality, the stage was set for a plunge in wave (c) long ago.

And just when the outlook was the bleakest, the bulls took the wheel and never looked back. Less than two years later, those who had the courage to buy Horizon Pharma stock below $10 a share multiplied their money by three.

The stock is still below its 2015 high, so we think the bulls’ chances of reaching $40 are quite good. How far can they go past this psychological mark is anyone’s guess at this point.

Did you like this analysis? Our Elliott Wave Video Course can teach you how to uncover the patterns yourself!

Stay informed with our newsletter

Latest Elliott Wave analysis on different topics delivered to you weekly.

Privacy policy
You may also like:

MongoDB – Bearish Pattern Joins Nosebleed Valuation

MongoDB Inc. is a general purpose database platform developer and provider. The company was founded in 2007, but only came public ten years later – in 2017. During the following four years, the stock has risen from an IPO price of $33 to $515 a share as of last week. So, it is fair to…

Read More »

Pandora Does Things Right. Stock May Need a Breather

When we wrote our previous article on Danish jewelry maker Pandora in December, 2020, the stock was up over three-fold since March. That recovery from DKK 180 to DKK 651 didn’t not come out of the blue, though. It was the result of a bullish setup we managed to identify as early as July 2019.…

Read More »

Match ‘s SP500 Inclusion a Good Excuse to Reach $200

Match Group Inc. rose over 10% in post-market trading Friday following reports that it is going to be included in the S&P 500. The company, which owns Tinder, OkCupid and most other major dating apps in the U.S., has a market cap of over $41B. Despite the anticipated “summer of love”, though, this is not…

Read More »

Cameco Stock Seems to Have Finally Turned a Corner

Uranium spot prices are on the verge of breaking above $34/lb, up over 80% from the bottom of $18/lb reached in late-2016. Cameco, as one of the world’s top uranium producers, is now seeing its stock price rising in tandem. Yesterday, it closed at $19.16 after reaching $21.95 in June. We first covered Cameco in…

Read More »

A Fresh Look At Cigna ‘s Elliott Wave Super Cycle

In a case study article on Cigna, published in October, 2016, we examined how a fundamentally sound and undervalued stock can still drop nearly 90%. The reason for that crash didn’t lie in some company specific issue. Rather it happened to occur during the biggest financial crisis in 80 years. Nevertheless, we made the point…

Read More »

CBOE Takeover Rumor Lifts Stock to Elliott Wave Target

We first wrote about CBOE Global Markets less than eight months ago. The S&P 500 had already recouped all its COVID selloff losses and was hovering at new all-time highs. CBOE, in contrast, was still down 30% from its 2018 record, trading below $97 a share. For some reason, the market was ignoring the company’s…

Read More »

Ahead of Ulta Beauty ‘s 150% Gain Since Lockdown

Buying shares in a beauty retailer in March 2020 sounded like a crazy, stupid idea. Stock markets around the world were plunging at a record pace amid a global GDP crash resulting from government-enforced lockdowns. People were stockpiling necessities in preparations not to leave their homes in the foreseeable future. With COVID-19 cases rising everywhere,…

Read More »

More analyses